GlaxoSmithKline PLC
LSE:GSK

Watchlist Manager
GlaxoSmithKline PLC Logo
GlaxoSmithKline PLC
LSE:GSK
Watchlist
Price: 1 342 GBX 2.48% Market Closed
Market Cap: 54.7B GBX
Have any thoughts about
GlaxoSmithKline PLC?
Write Note

Relative Value

The Relative Value of one GSK stock under the Base Case scenario is 2 580.36 GBX. Compared to the current market price of 1 342 GBX, GlaxoSmithKline PLC is Undervalued by 48%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

GSK Relative Value
Base Case
2 580.36 GBX
Undervaluation 48%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
90
vs Industry
52
Median 3Y
2
Median 5Y
2
Industry
2.5
Forward
1.7
vs History
34
vs Industry
31
Median 3Y
12.4
Median 5Y
12
Industry
21.9
Forward
8.5
vs History
71
vs Industry
39
Median 3Y
7.9
Median 5Y
7.9
Industry
16.5
vs History
vs Industry
12
Median 3Y
26.2
Median 5Y
19.2
Industry
23.6
vs History
82
vs Industry
17
Median 3Y
4.4
Median 5Y
4.5
Industry
2.1
vs History
95
vs Industry
44
Median 3Y
2.3
Median 5Y
2.4
Industry
2.6
Forward
2
vs History
98
vs Industry
56
Median 3Y
3.4
Median 5Y
3.5
Industry
5.2
vs History
96
vs Industry
40
Median 3Y
6.9
Median 5Y
7.1
Industry
13.3
Forward
6.2
vs History
90
vs Industry
36
Median 3Y
9.5
Median 5Y
9.8
Industry
16.6
Forward
7.4
vs History
79
vs Industry
37
Median 3Y
9.7
Median 5Y
9.8
Industry
15.6
vs History
73
vs Industry
25
Median 3Y
15
Median 5Y
14.1
Industry
19.1
vs History
44
vs Industry
38
Median 3Y
1.8
Median 5Y
1.5
Industry
1.9

Multiples Across Competitors

GSK Competitors Multiples
GlaxoSmithKline PLC Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
UK
GlaxoSmithKline PLC
LSE:GSK
54.7B GBP 1.7 13.6 6.2 8.6
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY 4 211 733 -5 347 888.9 -5 459 134.4 -5 046 864.6
US
Eli Lilly and Co
NYSE:LLY
710.5B USD 17.4 84.9 45.7 51
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
DK
Novo Nordisk A/S
CSE:NOVO B
3.3T DKK 12.3 35 24.3 27.8
US
Johnson & Johnson
NYSE:JNJ
373.5B USD 4.3 25.4 12.3 16
US
Merck & Co Inc
NYSE:MRK
251.1B USD 4 20.7 10.5 12.5
CH
Roche Holding AG
SIX:ROG
202.7B CHF 3.5 17.6 9.9 11.8
CH
Novartis AG
SIX:NOVN
183.3B CHF 4.1 11.6 10.1 14
UK
AstraZeneca PLC
LSE:AZN
162.4B GBP 4.1 31.6 169.4 253.9
IE
Endo International PLC
LSE:0Y5F
146B USD 63 -49.9 234.4 587.7
P/E Multiple
Earnings Growth
UK
GlaxoSmithKline PLC
LSE:GSK
Average P/E: 30.1
13.6
61%
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 347 888.9 N/A
US
Eli Lilly and Co
NYSE:LLY
84.9
451%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A
DK
Novo Nordisk A/S
CSE:NOVO B
35
86%
US
Johnson & Johnson
NYSE:JNJ
25.4
-22%
US
Merck & Co Inc
NYSE:MRK
20.7
7 321%
CH
Roche Holding AG
SIX:ROG
17.6
32%
CH
Novartis AG
SIX:NOVN
11.6
21%
UK
AstraZeneca PLC
LSE:AZN
31.6
177%
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -49.9 N/A

See Also

Discover More
Back to Top